All articles by Annabel Kartal Allen

Annabel Kartal Allen

Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel

MHRA homes in on personalised healthcare and tech in new 2030 strategy

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has devised a new strategy to better harness advancements in personalised…
Women’s health landscape shifting, but systemic hurdles remain

It is no secret that research and development (R&D) efforts to improve care in women’s health have long been critically…
Mirum tees up Livmarli label expansion on Phase III liver disease study success

Mirum Pharmaceuticals’ marketed therapy, Livmarli (maralixibat), could be poised for a label expansion, after the drug secured a resounding success…
AstraZeneca pins bone disease drug’s Phase III failure on high placebo response

AstraZeneca’s enzyme replacement therapy (ERT) candidate, efzimfotase alfa, has failed to demonstrate significant benefits over placebo in a late-stage trial…
Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact

California-based biopharma company Alumis has debuted data from a trio of Phase III studies that the company says highlights the…

Argenx cans Phase III Vyvgart Sjögren’s study on predicted efficacy fail

Argenx has terminated a late-stage trial evaluating its marketed therapy, Vyvgart Hytrulo (efgartigimod alfa, hyaluronidase-qvfc) in Sjögren's syndrome – dashing…
Cerevance’s novel Parkinson’s drug nets a Phase III win

Boston-based biotech Cerevance’s first-in-class Parkinson’s therapy, solengepras, has demonstrated its potential to improve both motor and non-motor symptoms in a…
Eye implant sight improvements in GA continue for 36 months, pivotal study finds

Science Corporation’s subretinal implant and specialised glasses combination, PRIMA, has been shown to provide durable, long-term gains in vision to…
EADV26: Key late-stage readouts from the conference

In recent years, there has been an explosion in the range of therapies for immunological diseases, with the treatment paradigm…
Brainomix’s e-Lung shows progression and treatment response in Phase III trial

Brainomix has debuted data from a Phase III progressive pulmonary fibrosis (PPF) study that highlights the ability of its AI-powered…